Dec 30, 2025 • Express Pharma
BULLISH
Mr Gurupyar Reddy, Head-Production Complex Injections, Dr Reddy's Laboratories
Mr. Gurupyar Reddy, Head-Production Complex Injections at Dr. Reddy's Laboratories, spoke at the Vizag Pharma Summit 2025. He highlighted the critical role of advanced drug delivery systems like NDDS in enhancing drug efficacy, improving patient outcomes, and contributing to the future value of pharmaceutical innovation.
Dec 30, 2025 • scanx.trade
NEUTRAL
Dr Reddy's Laboratories Board to Consider Q3 Results on January 21
Dr Reddy's Laboratories has scheduled a board meeting for January 21, 2026, to review and approve its third-quarter financial results. This meeting is a standard corporate governance practice and is crucial for providing insights into the company's operational performance and financial health. Investors, analysts, and industry observers will closely monitor these results, as Dr Reddy's is a prominent pharmaceutical company in India.
Dec 30, 2025 • The Economic Times
SOMEWHAT-BULLISH
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories posts solid returns
This article provides live updates on Dr. Reddy's Laboratories (Dr Reddys) stock performance, including current price, daily changes, and moving averages. It highlights a recent analyst recommendation suggesting a potential upside and notes the stock's performance over various timeframes, such as a 2.75% return over the last three months despite recent minor declines.
Dec 29, 2025 • The Economic Times
NEUTRAL
Dr Reddys Share Price Live Updates: Dr. Reddy's Moves Past 100-Day SMA Mark
This article provides live updates on Dr. Reddy's stock performance on December 29, 2025, detailing its share price movements, dividend information, and technical indicators. Key updates show the stock fluctuating, at one point moving past its 100-day Simple Moving Average, and later dipping below its 100-day and 20-day Exponential Moving Averages, reflecting daily changes and longer-term returns.
Dec 25, 2025 • The Economic Times
SOMEWHAT-BEARISH
Dr Reddys Share Price Live Updates: Choice Equity Broking Issues New Rating for Dr. Reddy's
Dr. Reddy's Laboratories has received a new "buy" rating from Choice Equity Broking Private Ltd, with a target price of Rs 1380.0, indicating a potential upside of 9.27%. The stock experienced a decline of 1.28% for the day, closing at Rs 1267.1. Throughout the day, Dr. Reddy's shares consistently showed a downward trend, trading below key moving averages and support levels.
Dec 24, 2025 • ET Now
NEUTRAL
Top Gainers and Losers Today, 24 December 2025: Trent Ltd, Shriram Finance Ltd lead gains; Interglobe Aviation Ltd, Dr Reddys Laboratories Ltd among top losers
On December 24, 2025, Trent Ltd and Shriram Finance Ltd led the gains in the Indian stock market, while Interglobe Aviation Ltd and Dr Reddys Laboratories Ltd were among the top losers. The Sensex and Nifty 50 both saw slight declines, with the Sensex down by 0.14% and the Nifty 50 down by 0.13%. The article provides detailed lists of the top-performing and underperforming stocks, along with key index performance metrics.